SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
From the Blogosphere
Unusual 11 Mid-Day Movers 5/4: ACAD, XTXI, CDII, NCOC Higher; FXP, BCRX, ATCO, CCC Lower
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) <font>137% HIGHER;</font> today announced it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE: BVF), to co-develop and commercialize pimavanserin, ACADIA's proprietary and selective 5-HT2A inverse agonist, in the United States and Canada. Under the terms of the collaboration, ACADIA is entitled to receive aggregate payments, excluding royalties, of up to $395 million. Click here for the full report.Crosstex Energy (Nasdaq: XTXI) <font>42.3% HIGHER;</font> the stock is spiking tod...
|
Morning Movers 5/4: ACAD, CPSL, NAFC, LIZ, FREE, CYOU Higher; CCC, CPST Lower
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) <font>123% HIGHER;</font> today announced it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE: BVF), to co-develop and commercialize pimavanserin, ACADIA's proprietary and selective 5-HT2A inverse agonist, in the United States and Canada. Under the terms of the collaboration, ACADIA is entitled to receive aggregate payments, excluding royalties, of up to $395 million. Click here for the full report.China Precision Steel (Nasdaq: CPSL) <font>20.5% HIGHER;</font> the commodities se...
|
Morning Movers 5/4: ACAD, NAFC, LIZ, FREE, CYOU Higher; CCC, CPST Lower
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) <font>123% HIGHER;</font> today announced it has established a collaboration with Biovail Laboratories International SRL, a subsidiary of Biovail Corporation (NYSE: BVF), to co-develop and commercialize pimavanserin, ACADIA's proprietary and selective 5-HT2A inverse agonist, in the United States and Canada. Under the terms of the collaboration, ACADIA is entitled to receive aggregate payments, excluding royalties, of up to $395 million. Click here for the full report.Nash Finch (Nasdaq: NAFC) 18.4% HIGHER; reports Q1 EPS of $0.46, 3 cents below the...
|
Biovail -(BVF) - breaks out / Ruptura
|
|
|
English-
BVF - breaks out to the upside with volume. Indicators shown are showing a possible continuation to the upside. Enter longs above the high of the day (11.81) for a 13.00 price target.
Español-
BVF - ruptura alcista con volumen. Los indicadores puesto dan señales alcistas. Entrar en largos por encima del maximo de hoy (11.81) para un objetivo a muy corto plazo de 13.00
|
Biovail: Upside Potential, High Dividend Yield
Quarterly Result Summary:
- Revenue fell to $181.5 million from $203.9 million a year earlier, hurt by declining sales of key treatments.
- Considers nominating new members to the board and change some corporate governance provisions.
- 76 cents a share, during the quarter, compared with a loss of $32 million, or 20 cents a share a year earlier
- Excluding charges, earned 34 cents a share, down from $72.5 million, or 45 cents a share
<><>Overall, Biovail (BVF) was showing weak results due to competition from generic drugs. For example, sales of its Wellbutrin antidepressant drug fell 66%. R...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
Be the first to start a discussion and earn 2 points.
More Resources
|
About Biovail Corp.
- Answers.com
